CareDx announced successful IVDR certification in the European Union for its AlloSeq Tx and QType platforms, which leverage next-generation sequencing and RT-PCR technologies for enhanced human leukocyte antigen (HLA) typing in organ and stem cell transplantation. Innovations include expanded Class II coverage, integration of non-HLA markers, rapid ABO typing, and software upgrades supporting regulatory compliance. These advancements reinforce CareDx’s leadership in transplant diagnostics and aim to improve donor-recipient matching accuracy globally.